12:00 AM
Apr 29, 2013
 |  BC Week In Review  |  Company News  |  Deals

Epizyme, Abbott deal

The companies partnered to develop a companion diagnostic for Epizyme's EPZ-5676. The histone methyltransferase DOT1L (DOT1L) inhibitor is in a Phase I trial to treat leukemia with rearrangements in the histone methyltransferase

Read the full 166 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >